My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Journal of Negative and No Positive Results
On-line version ISSN 2529-850X
Abstract
OCANTO, Abrahams et al. Chemoradiotherapy in rectal cancer and pathological response. JONNPR [online]. 2020, vol.5, n.11, pp.1378-1389. Epub Dec 18, 2023. ISSN 2529-850X. https://dx.doi.org/10.19230/jonnpr.3812.
Introduction.
Neoadjuvant treatment with radiotherapy and radiosensitizing chemotherapy in locally advanced rectal cancer (LARC) significantly decreases local recurrence rates. Therefore the objective of this study is to analyze the pathological complete response (PCR) and partial response (PPR) of neoadjuvant treatment with exclusive chemoradiotherapy in patients with locally advanced rectal cancer. Matherial and Method. It has been made a study descriptive, retrospective in a cohort of patients with LARC in the January 2016 to December 2018 period in the Radiation-Oncology Department of Hospital Universitario La Paz. 140 patients were included. A group of patients (92,9%) received treatment with radiotherapy 3D conformed technique with a dose administered the 45 Gy on pelvis and a boost of 5,4 Gy on tumor and other group (7,1%) received treatment with volumetric archotherapy radiotherapy (VMAT) guided by image (IGRT) with a dose administered of 53,7% on pelvis with concurrent boost and. The dose of capecitabine was 850 mg/m2, twice a day during the treatment. The patients were re-evaluated with post-neoadjuvant MRI. Patients were operated 6 to 8 weeks post chemoradiotherapy.
Results.
CPR was obtained of 17,1% and pPR of 80,1% with a global rate downstaging of 31,8%.
Conclusion.
It concludes that chemoradiotherapy neoadjuvant is a safe treatment with acceptable rates of local control in patients with LARC.
Keywords : chemoradiotherapy; cancer of rectum; radiotherapy; cancer.